Targeting the microenvironment

References

• Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci 2005;10:1581–1596.
   PubMed Web of Science ®Google Scholar
• Dührsen U, Hossfeld DK. Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol 1996;73:53–70.
   PubMed Web of Science ®Google Scholar
• Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003;17:1961–1966.
   PubMed Web of Science ®Google Scholar
• Bisping G, Leo R, Wenning D, et al Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101:2775–2783.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Sordillo EM, Yaccoby S, et al Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581–11586.
   PubMed Web of Science ®Google Scholar
• Fortney JE, Hall BM, Bartrug L, Gibson LF. Chemotherapy induces bcl-2 cleavage in lymphoid leukemic cell lines. Leuk Lymphoma 2002;43:2171–2178.
   PubMed Web of Science ®Google Scholar
• Wang L, Fortney JE, Gibson LF. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res 2004;28:733–742.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Takemoto N, Sato T, et al Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9:1158–1165.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Wilder RB, Levy LB, et al Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004;27:73–80.
   PubMed Web of Science ®Google Scholar
• Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351–6357.
   PubMed Web of Science ®Google Scholar
• Kuppers R. The biology of Hodgkin's lymphoma R. Nat Rev Cancer 2009;9:15–27.
   PubMed Web of Science ®Google Scholar
• Enblad G, Molin D, Glimelius I, Fischer M, Nilsson G. The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:805–823.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Mounier N, Brice P, et al Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:1732–1740.
   PubMed Web of Science ®Google Scholar
• Devilard E, Bertucci F, Trempat P, et al Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095–3102.
   PubMed Web of Science ®Google Scholar
• Chetaille B, Bertucci F, Finetti P, et al Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765–2775.
   PubMed Web of Science ®Google Scholar
• Sanchez-Aguilera A, Montalban C, de la Cueva P, et al Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662–668.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, Farinha P, et al Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Duff MD, Mestre J, Maddali S, Zhao PY, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. J Surg Res 2007;142:119–128.
   PubMedGoogle Scholar
• Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177:7303–7311.
   PubMed Web of Science ®Google Scholar
• Oki Y, Pro B, Fayad LE, et al Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831–836.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, et al A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310–314.
   PubMed Web of Science ®Google Scholar
• Marafioti T, Hummel M, Foss HD, et al Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443–1450.
   PubMed Web of Science ®Google Scholar
• Newcom SR, Kadin ME, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. Int J Cell Cloning 1988;6:417–431.
   PubMedGoogle Scholar
• Jones RJ, Gocke CD, Kasamon YL, et al Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920–5926.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Han WCC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Le Page E, Brière J, et al Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Moehler TM, Ho AD, Goldschmidt H, et al Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227–244.
   PubMed Web of Science ®Google Scholar